Pain response in a population-based study of radium-223 (Ra223) for metastatic castration-resistant prostate cancer.
Parimi S, Bondy S, Tsang E, McKenzie MR, Bachand F, Aparicio M, Duncan G, Sunderland K, Olson RA, Pai HH, Alexander AS, LaPointe V, Chi KN, Tyldesley S.
Parimi S, et al. Among authors: lapointe v.
Can Urol Assoc J. 2019 Oct;13(10):E311-E316. doi: 10.5489/cuaj.5685.
Can Urol Assoc J. 2019.
PMID: 31364977
Free PMC article.